Peg-IFNα2a

DRUG3 trials

Sponsors

Debiopharm International SA

Conditions

Chronic Hepatitis CHepatitis CLiver Disease

Phase 2

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

CompletedNCT00537407

Debiopharm International SAChronic Hepatitis C

Start: 2007-09-30End: 2010-04-30Updated: 2016-02-17

Unknown Phase

A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients

CompletedNCT00854802

Debiopharm International SAChronic Hepatitis C

Start: 2009-01-31End: 2010-09-30Updated: 2016-02-17

Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients

CompletedNCT01970904

Debiopharm International SAHepatitis C, Liver Disease

Start: 2013-10-31End: 2015-03-31Updated: 2016-04-20